| Literature DB >> 23667420 |
Hung-Cheng Shih1, Tsong-Long Hwang, Hung-Chung Chen, Ping-Chung Kuo, E-Jian Lee, Kuo-Hsiung Lee, Tian-Shung Wu.
Abstract
Two honokiol dimers, houpulins A and B (1 and 2), and two magnolol derivatives, houpulins C and D (3 and 4), were isolated and characterized from an ethanol extract obtained from the roots of Magnolia officinalis. The chemical structures were determined based on spectroscopic and physicochemical analyses, which included 1D and 2D NMR, as well as mass spectrometry data. These four oligomers possess new carbon skeletons postulated to be biosynthesized from the coupling of three or four C6-C3 subunits. In addition, the new oligomers were evaluated for inhibition of superoxide anion generation and elastase release, and houpulin B (2) was identified as a new anti-inflammatory lead compound.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23667420 PMCID: PMC3646836 DOI: 10.1371/journal.pone.0059502
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
1H and 13C Spectroscopic Data of 1–4.
| 1 | 2 | 3 | 4 | |||||
| position | δH mult. ( | δC | δH mult. ( | δC | δH mult. ( | δC | δH mult. ( | δC |
| 1 | 132.2 | 132.1 | 132.1 | 131.7 | ||||
| 2 | 7.13 d (2.2) | 131.4 | 7.12 d (2.2) | 131.2 | 7.08 d (2.4) | 131.3 | 7.03 d (2.2) | 132.4 |
| 3 | 129.1 | 128.9 | 126.6 | 127.1 | ||||
| 4 | 153.3 | 153.2 | 152.1 | 153.8 | ||||
| 5 | 6.88 d (8.1) | 117.0 | 6.88 d (8.2) | 116.9 | 6.88 d (8.3) | 117.5 | 6.80 d (8.18) | 117.1 |
| 6 | 7.00 dd (8.1, 2.2 ) | 128.9 | 6.97 dd (8.2, 2.2 ) | 128.8 | 7.09 dd (8.3, 2.4 ) | 129.1 | 6.96 dd (2.2, 8.18) | 129.3 |
| 7 | 3.34 d ( 6.7) | 40.1 | 3.33 d (6.7) | 40.0 | 3.34 brd | 39.5 | 3.23 d (6.7) | 40.0 |
| 8 | 5.96 m | 139.3 | 5.96 m | 139.2 | 5.04 m | 137.9 | 6.00 m | 139.2 |
| 9 | 5.00 m | 115.5 | 5.02 m | 115.4 | 5.95 m | 115.7 | 4.98 m | 115.4 |
| 1' | 128.6 | 128.5 | 132.9 | 132.5 | ||||
| 2' | 151.9 | 7.37 brs | 131.4 | 6.99 brs | 130.5 | 6.95 brs | 130.6 | |
| 3' | 127.6 | 7.37 brs | 126.1 | 126.4 | 127.8 | |||
| 4' | 7.36 d (2.2) | 131.3 | 131.2 | 149.6 | 151.5 | |||
| 5' | 131.0 | 131.7 | 122.3 | 123.2 | ||||
| 6' | 7.37 d (2.2) | 131.1 | 151.7 | 6.96 brs | 129.4 | 6.95brs | 129.8 | |
| 7' | 3.51 d (6.7) | 35.6 | 35.4 | 3.36 brd | 39.4 | 40.9 | ||
| 8' | 6.10 m | 138.0 | 137.9 | 5.11 m | 137.6 | 139.2 | ||
| 9' | 5.14 m | 115.8 | 115.8 | 6.00 m | 115.7 | 115.6 | ||
| 1'' | 133.2 | 132.8 | 134.8 | |||||
| 2'' | 7.09 brs | 131.4 | 7.20 d (8.69) | 127.4 | 7.35 d (2.1) | 130.3 | ||
| 3'' | 131.8 | 6.70 d (8.69) | 115.4 | 127.1 | ||||
| 4'' | 149.6 | 155.4 | 154.4 | |||||
| 5'' | 126.9 | 6.70 d (8.69) | 115.4 | 6.94 d (8.1) | 117.4 | |||
| 6'' | 7.09 brs | 131.4 | 7.20 d (8.69) | 127.4 | 7.32 dd (8.1, 2.1 ) | 127.4 | ||
| 7'' | 3.39 d (7.0) | 40.1 | 5.07 m | 78.5 | 5.12 m | 78.7 | ||
| 8'' | 6.00 m | 139.1 | a: 2.25 mb: 2.15 m | 29.4 | a: 2.29 mb: 2.10 m | 30.6 | ||
| 9'' | 5.03 m | 115.6 | a: 3.04 mb: 2.89 m | 25.2 | a: 3.08 mb: 2.87 m | 26.2 | ||
| 1''' | 127.2 | 132.9 | ||||||
| 2''' | 7.32 d (2.1) | 132.0 | 7.09 d (1.8) | 132.7 | ||||
| 3''' | 130.6 | 127.1 | ||||||
| 4''' | 7.28 dd (2.1, 8.1) | 129.4 | 153.1 | |||||
| 5''' | 6.91 d (8.1) | 115.8 | 6.92 d (8.1) | 117.4 | ||||
| 6''' | 155.2 | 7.05 dd (8.1, 1.8) | 129.7 | |||||
| 7''' | 3.43 d (6.7) | 35.1 | 3.37 d (7.6) | 40.1 | ||||
| 8''' | 6.04 m | 138.1 | 5.90 m | 139.1 | ||||
| 9''' | 5.08 m | 115.7 | 5.03 m | 115.5 | ||||
a: δ (ppm); 400 MHz for 1H and 100 MHz for 13C; acetone-d6; J values (Hz) in parentheses.
b: δ (ppm); 500 MHz for 1H and 125 MHz for 13C; CDCl3; J values (Hz) in parentheses.
Figure 1Structures of 1–4.
Figure 2Plausible biosynthetic pathway to 1 and 2.
Inhibitory effects of 1–4 on superoxide anion generation and elastase release by human neutrophils in response to FMLP/CB.
| compound | IC50 (µM) | |
| superoxide anion generation | elastase release | |
|
| 3.2±0.16 | 2.3±0.17 |
|
| 2.9±0.16 | 2.0±0.50 |
|
| - | 3.4±0.53 |
|
| 12.7±4.11 | 8.7±1.15 |
|
| 19.5±1.40 | 8.5±2.87 |
|
| - | 5.7±1.30 |
| sorafenib | 3.2±0.42 | 2.0±0.13 |
Concentration necessary for 50% inhibition. Results are presented as the mean ± S.D. (n = 3).
P<0.001 compared with the control value.
Alone induced superoxide generation by human neutrophils.
Sorafenib, a tyrosine kinase inhibitor, was used as a positive control.
Figure 3Compound 2 did not alter activation of ERK, p38 MAPK, JNK, and Akt.
Figure 4[Ca2+]i to return to half of the peak value (t 1/2) by compound 2.